Clinical Report: Parasutterella excrementihominis and Colitis-Related Cancer

Overview

This study identifies Parasutterella excrementihominis as a contributor to experimental colitis and colitis-associated colorectal cancer through the induction of pathogenic NETosis. The findings suggest that metabolites produced by this bacterium activate inflammatory pathways, linking gut microbiota to disease progression.

Background

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that significantly increases the risk of colitis-associated colorectal cancer (CAC). The role of specific gut microbiota, particularly Parasutterella excrementihominis, in exacerbating inflammation and promoting cancer progression is not well understood. Understanding these mechanisms is crucial for developing targeted therapies for UC and CAC.

Data Highlights

No numerical data available in the source material.

Key Findings

• P. excrementihominis is enriched in UC patients and correlates with disease activity.
• This bacterium exacerbates experimental colitis and CAC through the production of succinic acid and 6-hydroxyhexanoic acid.
• These metabolites activate gasdermin D-dependent NETosis via specific signaling pathways.
• Dysregulated NETosis contributes to mucosal damage and inflammation in UC.
• Targeting P. excrementihominis or its metabolites may provide novel therapeutic strategies for UC and CAC.

Clinical Implications

Clinicians should consider the role of gut microbiota, particularly P. excrementihominis, in the management of UC and CAC. Targeting this bacterium or its metabolites could represent a new therapeutic approach to mitigate inflammation and cancer risk in affected patients.

Conclusion

The study highlights the pathogenic role of P. excrementihominis in UC and CAC, emphasizing the need for further research into microbiota-targeted therapies. Understanding these mechanisms may lead to improved clinical outcomes for patients with inflammatory bowel diseases.

References

1. Journal of Crohn's and Colitis, 2023 -- Susceptibility to inflammatory bowel diseases promotes invasive carcinomas in a murine model of ATF6-driven colon cancer
2. Archives of Toxicology, 2021 -- Chronic Inflammation of the Intestine Promotes Colorectal Tumor Development Induced by Dietary Heme Iron in Vivo
3. Journal of Crohn's and Colitis, 2021 -- The Impact of Peptidyl Arginine Deiminase 4-Dependent Neutrophil Extracellular Trap Formation on the Early Development of Intestinal Fibrosis in Crohn’s Disease
4. Living guideline for pharmacological management of moderate-to-severe ulcerative colitis - American Gastroenterological Association, 2025
5. Models for Assessing Intestinal Anastomosis Healing in Experimental Colitis
6. Neutrophils and NETs in Pathophysiology and Treatment of Inflammatory Bowel Disease
7. Living guideline for pharmacological management of moderate-to-severe ulcerative colitis - American Gastroenterological Association